Calcineurin inhibitors and Clostridium difficile infection in adult lung transplant recipients: The effect of cyclosporine versus tacrolimus

Journal of Surgical Research

Volumn 184, Issue 1, 2013, Pages 599-604

  Lee, Janet T ^a   Whitson, Bryan A ^b   Kelly, Rosemary F ^a   D'Cunha, Jonathan ^c   Dunitz, Jordan M ^a   Hertz, Marshall I ^a   Shumway, Sara J ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Calcineurin inhibitors; Clostridium difficile; Cyclosporine; Immunosuppression; Lung transplantation; Tacrolimus; Transplant infections

Indexed keywords

ACICLOVIR; CALCINEURIN INHIBITOR; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOSPORIN; DAPSONE; METRONIDAZOLE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; VALGANCICLOVIR;

ADOLESCENT; ADULT; AGED; ALPHA 1 ANTITRYPSIN DEFICIENCY; ARTICLE; BLOOD TRANSFUSION; CARDIOPULMONARY BYPASS; CHILD; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLOSTRIDIUM DIFFICILE INFECTION; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CYSTIC FIBROSIS; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; DRUG SAFETY; FEMALE; FIBROSING ALVEOLITIS; GRAFT RECIPIENT; HEART LUNG TRANSPLANTATION; HOSPITALIZATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INTENSIVE CARE UNIT; LENGTH OF STAY; LUNG GRAFT REJECTION; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PNEUMOCYSTOSIS; POSTOPERATIVE CARE; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; RECURRENCE RISK; RECURRENT INFECTION; RETROSPECTIVE STUDY; SCHOOL CHILD; SURGICAL INFECTION;

EID: 84884671478     PISSN: 00224804     EISSN: 10958673     Source Type: Journal    
DOI: 10.1016/j.jss.2013.03.041     Document Type: Article

References (27)

1. Christie JD, Edwards LB, Kucheryavaya AY, et al. The Registry of the International Society for Heart and Lung Transplantation: 27th official adult lung and heartelung transplantation report- 2010. J Heart Lung Transpl 2010;29: 1104.
2. Christie JK, Edwards LB, Kucheryavaya AY, et al. The Registry of the International Society for Heart and Lung Transplantation: 29th adult lung and heart-lung transplant report- 2012. J Heart Lung Transpl 2012;31:1073.
3. Boehler A, Estenne M. Post-transplant bronchiolitis obliterans. Eur Respir J 2003;22:1007.
4. Zuckermann A, Reichenspurner H, Birsan T, et al. Cyclosporine A versus tacrolimus in combination with mycophenolate mofetil and steroids as primary immunosuppression after lung transplantation: one-year results of 2-center prospective randomized trial. J Thorac Cardiovasc Surg 2003;125:891.
5. Treede H, Glanville AR, Klepetko W, et al. Tacrolimus and cyclosporine have differential effects on the risk of development of bronchiolitis obliterans syndrome: results of a prospective, randomized international trial in lung transplantation. J Heart Lung Transpl 2012;31:797.
6. Hachem RR, Yusen RD, Murali MC, et al. A randomized controlled trial of tacrolimus versus cyclosporine after lung transplantation. J Heart Lung Transpl 2007;26:1012.
7. Keenan RJ, Konishi H, Kawai A, et al. Clinical trial of tacrolimus versus cyclosporine in lung transplantation. Ann Thorac Surg 1995;60:580.
8. Treede H, Klepetko W, Reichenspurner H, et al. Tacrolimus versus cyclosporine after lung transplantation: a prospective, open, randomized two-center trial comparing two different immunosuppressive protocols. J Heart Lung Transpl 2001;20:511.
9. Boutros M, Al-Shaibi M, Chan G, et al. Clostridium difficile colitis: increasing incidence, risk factors, and outcomes in solid organ transplant recipients. Transplantation 2012;93:1051.
10. Gunderson CC, Gupta MR, Lopez F, et al. Clostridium difficile colitis in lung transplantation. Transpl Infect Dis 2008;10:245.
11. Pant C, Anderson MP, O?Connor JA, Marshall CM, Deshpande A, Sferra TJ. Association of Clostridium difficile infection with outcomes of hospitalized solid organ transplant recipients: results from the 2009 Nationwide Inpatient Sample database. Transpl Infect Dis 2012;14:540.
12. Ali M, Ananthakrishnan AN, Ahmad S, Kumar N, Kumar G, Saeian K. Clostridium difficile infection in hospitalized liver transplant patients: a nationwide analysis. Liver Transpl 2012;18:972.
13. Stelzmueller I, Goegele H, Biebl M, et al. Clostridium difficile colitis in solid organ transplantationda single-center experience. Dig Dis Sci 2007;52:3231.
14. Fan Y, Xiao YB, Weng YG. Tacrolimus versus cyclosporine for adult lung transplant recipients: a meta-analysis. Transpl Proc 2009;41:1821.
15. Garey KW, Sethi S, Yadav Y, DuPont HL. Meta-analysis to assess risk factors for recurrent Clostridium difficile infection. J Hosp Infect 2008;70:298.
16. Bobo LD, Dubberke ER, Kollef M. Clostridium difficile in the ICU: the struggle continues. Chest 2011;140:1643.
17. Pepin J, Valiquette L, Cossette B. Mortality attributable to nosocomial Clostridium difficile-associated disease during an epidemic caused by a hypervirulent strain in Quebec. CMAJ 2005;173:1037.
18. Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol 2010;31: 431.
19. Dallal RM, Harbrecht BG, Boujoukas AJ, et al. Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complications. Ann Surg 2002;235:363.
20. Theunissen C, Knoop C, Mpmjpff C, et al. Clostridium difficile colitis in cystic fibrosis patients with and without lung transplantation. Transpl Infect Dis 2008;10:240.
21. Lee JT, Hertz MI, Dunitz JM, et al. The rise of Clostridium difficile infection in lung transplant recipients in the modern era. Clin Transpl
22. Muto CA, Blank MK, Marsh JW, et al. Control of an outbreak of infection with the hypervirulent Clostridium difficile BI strain in a university hospital using a comprehensive "bundle" approach. Clin Infect Dis 2007;45:1266.
23. Daneman N, Stukel TA, Ma X, Vermeulen M, Guttman A. Reduction in Clostridiumdifficile infection rates aftermandatory hospital public reporting: findings froma longitudinal cohort study in Canada. PLoS Med 2012;9:e1001268.
24. Lessa FC, Gould CV, McDonald LC. Current status of Clostridium difficile infection epidemiology. Clin Infect Dis 2012;55:S65.
25. Gardiner DR, Rosenberg T, Zaharatos J, Franco D, Ho DD. A DNA vaccine targeting the receptor-binding domain of Clostridium difficile toxin A. Vaccine 2009;27:3598.
26. Wang H, Sun X, Zhang Y, et al. A chimeric toxin vaccine protects against primary and recurrent Clostridium difficile infection. Infect Immun 2012;80:2678.
27. Permpoonpattana P, Hong HA, Phetcharaburanin J, et al. Immunization with Bacillus spores expressing toxin A peptide repeats protects against infection with Clostridium difficile strains producing toxins A and B. Infect Immun 2011; 79:2295.